ecrin-mdr-crcClinical2011Colorectal Cancer, MetastaticColorectal NeoplasmsColorectal Cancer, MetastaticColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2115435United States9First lineFOLFOX6Bevacizumab5-FUECRIN MDRTerminatedfalseStudy Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6The purpose of this study is to compare OnDose based pharmacokinetic administration of 5-FU versus standard Body Surface Area (BSA) based administration of 5-FU in patients with metastatic colorectal cancer treated with mFOLFOX6, with or without bevacizumab, to determine if the use of OnDose achieves an improvement in the Overall Response Rate (ORR) relative to BSA dosing response.2011-09-152115435NCT01468623